TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone flu vaccine resuming plans to initiate Ph3 imminently. Q3 COVID vaccine revenues missed as expected, given delayed start as the low initial market share driving FY24 guidance down.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax price target lowered to $12 from $14 at BofA
- NVAX Earnings: Novavax Stock Down on Weak 2024 Revenue Outlook
- Novavax Advances Vaccine Strategy Amid Financial Shifts
- Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
- Novavax Resumes Phase 3 Vaccine Trials After FDA Hold